

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Please type a plus sign (+) inside this box → +

PTO/SB/81 (10-00)
Approved for use through 10/31/2002. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY OR
AUTHORIZATION OF AGENT**

Applicati n Number	09/773,374
Filing Date	February 1, 2001
First Nam d Inv nt r	Bing-Yan Zhu
Group Art Unit	1624
Examiner Name	Truong, T.N.
Attorney Docket Number	021390-001820US

RECEIVED

OCT 18 2002

TECH CENTER 1600/2900

I hereby appoint:

☒ Practitioners at Customer Number

20350

Place Customer
Number Bar Code
Label here

OR

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☒ The above-mentioned Customer Number.

OR

☐ Firm or
Individual Name

Address

Address

City

State

ZIP

Country

Telephone

Fax

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.

Certificate under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Name Robert Silverman

Signature


Date

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☒ *Total of 1 form is submitted.

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside thi



PTO/SB/82 (10-00)

Approved for use through 10/31/2002. OMB 0651-0035

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF ATTORNEY OR AUTHORIZATION OF AGENT	Application Number	09/773,374
	Filing Date	February 1, 2001
	First Named Inventor	Bing-Yan Zhu
	Group Art Unit	1624
	Examiner Name	Tamthom Ngo Truong
	Attorney Docket Number	021390-001820US

RECEIVED

OCT 18 2002

TECH CENTER 1600/2900

I hereby revoke all previous powers of attorney or authorizations of agent given in the above-identified application:

☒ A Power of Attorney or Authorization of Agent is submitted herewith.

OR

☐ Please change the correspondence address for the above-identified application to:

☐ Customer Number 20350

Place Customer
Number Bar Code
Label here

OR

<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City					
Country		State		ZIP	
Telephone		Fax			

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Certificate under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record


Name	Robert Silverman
Signature	<i>Robert Silverman</i>
Date	Sept. 3, 2002

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of forms are submitted.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WC 9045774 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/96 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Attorney Docket No. 021390-001820US
Client Ref. No. MPI00-594P1RN

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Bing-Yan Zhu and Robert M. Scarborough

Application No./Patent No.: 09/773,374

Filed/Issue Date: February 1, 2001

Entitled: 2-[1H]-QUINOLONE AND 2-[1H]-QUINOXALONE INHIBITORS OF FACTOR Xa

Millennium Pharmaceuticals, Inc., a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Bing-Yan Zhu and Robert M. Scarborough To: Cor Therapeutics, Inc.

The document was recorded in the United States Patent and Trademark Office at Reel 011781, Frame 0902, or for which a copy thereof is attached.

2. Merger of: Cor Therapeutics, Inc. Into: Millennium Pharmaceuticals, Inc.

A copy of the Certificate of Merger is attached.

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Sept. 3, 2002
Date

Robert Silverman

Typed or printed name

Robert Silverman


Signature

Sr. Patent Counsel

Title



UNITED STATES
PATENT AND
TRADEMARK OFFICE



RECEIVED

OCT 18 2002

MST
PATRU

AUGUST 13, 2002

PTAS

TECH CENTER 1600/2900

Chief Information Officer
Washington, DC 20231
www.uspto.gov

MORGAN, LEWIS & BOCKIUS LLP
MICHAEL S. TUSCAN P.H.
1111 PENNSYLVANIA AVE., NW
WASHINGTON, D.C. 20004



102122836A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 06/10/2002

REEL/FRAME: 012977/0516
NUMBER OF PAGES: 7

BRIEF: MERGER (SEE DOCUMENT FOR DETAILS):

ASSIGNOR:

COR THERAPEUTICS, INC.

DOC DATE: 02/12/2002

ASSIGNEE:

MILLENNIUM PHARMACEUTICALS, INC.
75 SIDNEY STREET
CAMBRIDGE, MASSACHUSETTS 02139

SERIAL NUMBER: 07808329 *44481-5002-01*
PATENT NUMBER:

FILING DATE: 12/16/1991
ISSUE DATE:

mst/mst/RJS
Abandoned

SERIAL NUMBER: 08477133 *44481-5002-06*
PATENT NUMBER:

FILING DATE: 06/07/1995
ISSUE DATE:

mst/mst/RJS
Lapsed

SERIAL NUMBER: 09362207 *44481-5002-14*
PATENT NUMBER:

FILING DATE: 07/28/1999
ISSUE DATE:

mst/mst/RJS
Abandoned

SERIAL NUMBER: 09671346 *44481-5002-15*
PATENT NUMBER:

FILING DATE: 09/27/2000
ISSUE DATE:

mst/mst/RJS

RECORDED

AUG 19 2002

MORGAN, LEWIS & BOCKIUS LLP

DOCKETED

By *SW* Date *9/4/02*

SERIAL NUMBER: 07854109	44481-5004	FILING DATE: 03/20/1992	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 08475262	44481-5004-02	FILING DATE: 06/07/1995	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09621004	44481-5004-04	FILING DATE: 07/20/2000	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 08390301	44481-5006-01	FILING DATE: 01/25/1995	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 08474414	44481-5006-02	FILING DATE: 06/07/1995	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 08486673	44481-5006-06	FILING DATE: 06/07/1995	MST/MST/RK
PATENT NUMBER: 6297026		ISSUE DATE: 10/02/2001	Closed
SERIAL NUMBER: 10127691	44481-5006-09	FILING DATE: 04/23/2002	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09035135	44481-5007-04	FILING DATE: 03/05/1998	MST/ECW/RJS
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 09801089	44481-5008-02	FILING DATE: 03/08/2001	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09410738	44481-5010-62	FILING DATE: 10/01/1999	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 09947922	44481-5010-03	FILING DATE: 09/07/2001	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 07801795	44481-5017	FILING DATE: 12/02/1991	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 08253440	44481-5017-01	FILING DATE: 06/07/1994	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 09419076	44481-5017-07	FILING DATE: 10/15/1999	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09585410	44481-5017-05	FILING DATE: 06/02/2000	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 08089455	44481-5018	FILING DATE: 07/09/1993	MST/ECW/RJS
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 08884571	44481-5018-03	FILING DATE: 06/27/1997	MST/ECW/RJS
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 09560814	44481-5018-04	FILING DATE: 04/28/2000	MST/ECW/RJS
PATENT NUMBER:		ISSUE DATE:	

SERIAL NUMBER: 09991888	44481-5025-03	FILING DATE: 11/26/2001	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09473716	44481-5027-01	FILING DATE: 12/29/1999	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09474076	44481-5028-01	FILING DATE: 12/29/1999	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 10071223	44481-5029-02	FILING DATE: 02/11/2002	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 08975653	44481-5039-02	FILING DATE: 11/21/1997	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09673302	44481-5043	FILING DATE: 03/23/2001	MST/ECW/SEZ
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09775803	44481-5044-01	FILING DATE: 02/05/2001	MST/ECW/SEZ
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09745842	44481-5053	FILING DATE: 12/26/2000	MST/MST/EDL
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 08948672	44481-5012	FILING DATE: 10/10/1997	
PATENT NUMBER: 6262047		ISSUE DATE: 07/17/2001	Transfer to T+T+C
SERIAL NUMBER: 09500231	44481-5015	FILING DATE: 02/08/2000	
PATENT NUMBER:		ISSUE DATE:	Transfer to T+T+C
SERIAL NUMBER: 09664535	44481-5061-99	FILING DATE: 09/18/2000	JAL/ECW/ECW
PATENT NUMBER:		ISSUE DATE:	ABANDONED
SERIAL NUMBER: 09663420	44481-5061	FILING DATE: 09/15/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 10126976	44481-5061-02	FILING DATE: 04/22/2002	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09226103	44481-5042	FILING DATE: 01/07/1999	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09501370	44481-5045	FILING DATE: 02/11/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09501371	44481-5045-01	FILING DATE: 02/11/2000	
PATENT NUMBER: 6399627		ISSUE DATE: 06/04/2002	Transferred to T+T+C
SERIAL NUMBER: 09576637	44481-5046	FILING DATE: 05/24/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09576634	44481-5046-01	FILING DATE: 05/24/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C

SERIAL NUMBER: 09576638 44481-5047	FILING DATE: 05/24/2000 Transferred
PATENT NUMBER:	ISSUE DATE: to T+T+C
SERIAL NUMBER: 09577131 44481-5047-01	FILING DATE: 05/24/2000 Transferred
PATENT NUMBER:	ISSUE DATE: to T+T+C
SERIAL NUMBER: 09576635 44481-5048	FILING DATE: 05/20/2000 Transferred
PATENT NUMBER:	ISSUE DATE: to T+T+C
SERIAL NUMBER: 09576636 44481-5048-01	FILING DATE: 05/24/2000 Transferred
PATENT NUMBER:	ISSUE DATE: to T+T+C
SERIAL NUMBER: 09576633 44481-5049	FILING DATE: 05/24/2000 Transferred
PATENT NUMBER:	ISSUE DATE: to T+T+C
SERIAL NUMBER: 09576632 44481-5049-01	FILING DATE: 05/24/2000 Transferred
PATENT NUMBER:	ISSUE DATE: to T+T+C
SERIAL NUMBER: 09577154 44481-5049-02	FILING DATE: 05/24/2000 Transferred
PATENT NUMBER:	ISSUE DATE: to T+T+C
SERIAL NUMBER: 09636804 44481-5050	FILING DATE: 08/10/2000 Transferred
PATENT NUMBER:	ISSUE DATE: to T+T+C
SERIAL NUMBER: 09662807 44481-5051	FILING DATE: 09/15/2000 Transferred
PATENT NUMBER:	ISSUE DATE: to T+T+C
SERIAL NUMBER: 09794214 44481-5051-01	FILING DATE: 02/28/2001 Transferred
PATENT NUMBER:	ISSUE DATE: to T+T+C
SERIAL NUMBER: 09714532 44481-5052	FILING DATE: 11/17/2000 Transferred to
PATENT NUMBER:	ISSUE DATE: T+T+C
SERIAL NUMBER: 09773383 44481-5055	FILING DATE: 02/01/2001 Transferred to
PATENT NUMBER:	ISSUE DATE: T+T+C
SERIAL NUMBER: 09773372 44481-5056	FILING DATE: 02/01/2001 Transferred to
PATENT NUMBER:	ISSUE DATE: T+T+C
SERIAL NUMBER: 09773373 44481-5057	FILING DATE: 02/01/2001 Transferred to
PATENT NUMBER:	ISSUE DATE: T+T+C
SERIAL NUMBER: 09773374 44481-5058	FILING DATE: 02/01/2001 Transferred to
PATENT NUMBER:	ISSUE DATE: T+T+C
SERIAL NUMBER: 09773375 44481-5059	FILING DATE: 02/01/2001 Transferred to
PATENT NUMBER:	ISSUE DATE: T+T+C
SERIAL NUMBER: 09775812 44481-5060	FILING DATE: 02/05/2001 Transferred to
PATENT NUMBER:	ISSUE DATE: T+T+C
SERIAL NUMBER: 09920325 44481-5060-01	FILING DATE: 08/02/2001 Transferred to
PATENT NUMBER:	ISSUE DATE: T+T+C

012977/0516 PAGE 5

SERIAL NUMBER: 09816782 44481-5062
PATENT NUMBER:

FILING DATE: 03/26/2001 Transferred
ISSUE DATE: to TTRC

SERIAL NUMBER: 09816771 44481-5063
PATENT NUMBER:

FILING DATE: 03/26/2001 Transferred to
ISSUE DATE: TTRC

SERIAL NUMBER: 09816781 44481-5064
PATENT NUMBER:

FILING DATE: 03/26/2001 Transferred to
ISSUE DATE: TTRC

TARA WASHINGTON, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS



06-14-2002



102122836

RECORDATION FORM
PATENTS ONLYMENT OF COMMERCE
ent and Trademark OfficeFORM PTO-1595
(Rev. 6-93)

Attorney Docket No.: 44481-0021-US

To the Assistant Commissioner for Patents:
Please record the attached original documents or copy thereof.

ATTN: BOX ASSIGNMENT

1. Name of conveying party(ies):

COR Therapeutics, Inc.

6-10-02

Additional name(s) of conveying party(ies) attached?

Yes ☒ No

2. Name and address of receiving party(ies):

Name: Millennium Pharmaceuticals, Inc.

Street Address: 75 Sidney Street

City: Cambridge State: MA

Country: US Zip: 02139

3. Nature of conveyance:

☐ Assignment ☒ Merger
☐ Security Agreement ☐ Change of Name
Other _____

Additional name(s) & address(es) attached?

Yes ☒ No

Execution Date(s): February 12, 2002

4. Application number(s) or patent number(s):

If this document is being filed together with a new application the execution date of the application is:

A. Patent Application No.(s): 07/808,329

B. Patent No.(s)

Additional numbers attached: ☒ Yes ☐ No See attached Schedule B.

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Michael S. Tuscan, Ph.D.
Internal Address: Customer No. 009629
Morgan, Lewis & Bockius LLPStreet Address: 1111 Pennsylvania Ave., NW
City: Washington State: D.C. Zip: 20004

6. Total number of applications and patents involved: 61

7. Total fee (37 C.F.R. §3.41): \$2440.00

☐ Enclosed☒ Authorized to be charged to deposit account 50-0310

8. Deposit account number: 50-0310

Attach duplicate of page if paying by deposit account

9. Statement and Signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Michael S. Tuscan, Ph.D., Reg. No. 43,210

Name of Person Signing

SignatureJune 10, 2002
Date

06/13/2002 DBYRNE 00000040 500310 07808329

Total number of pages including cover sheet, attachments and documents: 8

01 FCI:581 2440.00 CH

Schedule B, U.S. applications

Application No.	Filing Date	Title	Ref. No.
07/808,329	1991-12-16	Antithrombosis agents	44481-5002-01
08/477,133	1995-06-07	Agents affecting thrombosis and hemostasis	44481-5002-06
09/362,207	1999-07-28	Agents affecting thrombosis and hemostasis	44481-5002-14
09/671,346	2000-09-27	Agents affecting thrombosis and hemostasis	44481-5002-15
07/854,109	1992-03-20	Glycosylation-mediated inhibition of Factor X	44481-5004
08/475,262	1995-06-07	Glycosylation-mediated inhibition of Factor X	44481-5004-02
09/621,004	2000-07-20	Glycosylation-mediated inhibition of Factor X	44481-5004-04
08/390,301	1995-01-25	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-01
08/474,414	1995-06-07	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-02
08/486,673	1995-06-07	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-06
10/127,691	2002-04-23	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-09
09/035,135	1998-03-05	Process for production of inhibited forms of activated blood factors	44481-5007-04
09/801,089	2001-03-08	Modulation of integrin-mediated signal transduction	44481-5008-02
09/410,738	1999-10-01	Methods of screening for compounds that interact with human P _{2U2} purinergic receptor	44481-5010-02
09/947,922	2001-09-07	Methods of screening for compounds that interact with human P _{2U2} purinergic receptor	44481-5010-03
07/801,795	1991-12-02	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017
08/253,440	1994-06-07	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017-01
09/419,076	1999-10-15	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017-04
09/585,410	2000-06-02	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017-05
08/089,455	1993-07-09	Platelet glycoprotein V gene and uses	44481-5018
08/884,571	1997-06-27	Platelet glycoprotein V gene and uses	44481-5018-03
09/560,814	2000-04-28	Platelet glycoprotein V gene and uses	44481-5018-04

Schedule B, U.S. applications

Application No.	Filing Date	Title	Ref. No.
09/991,888	2001-11-26	Identification of Bap-1, a protein that binds to integrin and is Involved in integrin-mediated signal transduction	44481-5025-03
09/473,716	1999-12-29	Polynucleotides encoding a type V adenylyl cyclase	44481-5027-01
09/474,076	1999-12-29	Cloning and characterization of a human adenylyl cyclase	44481-5028-01
10/071,223	2002-02-11	Cloning and characterization of a human adenylyl cyclase	44481-5029-02
08/975,653	1997-11-21	Modulation of interactions between myosin and integrins	44481-5039-01
09/673,302	2001-03-23	Transgenic mammals expressing mutant GP IIIa	44481-5043
09/775,803	2001-02-05	Transgenic animals having a modified glycoprotein V gene	44481-5044
09/745,842	2000-12-26	P ₂ Y ₁₂ receptor	44481-5053
08/948,672	1997-10-10	Selective Factor Xa inhibitors	44481-5012-01
09/500,231	2000-02-08	Selective Factor Xa inhibitors	44481-5015-02
09/664,535	2000-09-18	Benzamides and related inhibitors of Factor Xa	44481-5061-99
09/663,420	2000-09-15	Benzamides and related inhibitors of Factor Xa	44481-5061
10/126,976	2002-04-22	Benzamides and related inhibitors of Factor Xa	44481-5061-02
09/226,103	1999-01-07	Platelet ADP receptor inhibitors	44481-5042
09/501,370	2000-02-11	Alkenyl and alkynyl compounds as inhibitors of Factor Xa	44481-5045
09/501,371	2000-02-11	Inhibitors of Factor Xa	44481-5045-01
09/576,637	2000-05-24	Inhibitors of Factor Xa	44481-5046
09/576,634	2000-05-24	Inhibitors of Factor Xa	44481-5046-01
09/576,638	2000-05-24	Inhibitors of Factor Xa	44481-5047
09/577,131	2000-05-24	Inhibitors of Factor Xa	44481-5047-01
09/576,635	2000-05-24	Inhibitors of Factor Xa	44481-5048
09/576,636	2000-05-24	Inhibitors of Factor Xa	44481-5048-01
09/576,633	2000-05-24	Inhibitors of Factor Xa	44481-5049
09/576,632	2000-05-24	Inhibitors of Factor Xa	44481-5049-01
09/577,154	2000-05-24	Inhibitors of Factor Xa	44481-5049-02
09/636,804	2000-08-10	Inhibitors of Factor Xa	44481-5050

Schedule B, U.S. applications

Application No.	Filing Date	Title	Ref. No.
09/662,807	2000-09-15	Inhibitors of Factor Xa	44481-5051
09/794,214	2001-02-28	Inhibitors of Factor Xa	44481-5051-01
09/714,532	2000-11-17	β -Amino acid-, aspartic acid- and diaminopropionic -based inhibitors of Factor Xa	44481-5052
09/773,383	2001-02-01	Indole and benzimidazole inhibitors of Factor Xa	44481-5055
09/773,372	2001-02-01	Indalone and benzimidazolone inhibitors of Factor Xa	44481-5056
09/773,373	2001-02-01	3,4-Dihydro-2h-benzo[1,4]oxazine inhibitors of Factor Xa	44481-5057
09/773,374	2001-02-01	2-[1H]-Quinolone and 2-[1H]-quinoxalone inhibitors of Factor Xa	44481-5058
09/773,375	2001-02-01	Bivalent phenylene inhibitors of Factor Xa	44481-5059
09/775,812	2001-02-05	Platelet ADP receptor inhibitors	44481-5060
09/920,325	2001-08-02	Platelet ADP receptor inhibitors	44481-5060-01
09/816,782	2001-03-26	Oxindole inhibitors of Factor Xa	44481-5062
09/816,771	2001-03-26	Isoquinolone inhibitors of Factor Xa	44481-5063
09/816,781	2001-03-26	Bicyclic sulfonyl amino inhibitors of Factor Xa	44481-5064

Delaware

PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF OWNERSHIP, WHICH MERGES:

"COR THERAPEUTICS, INC.", A DELAWARE CORPORATION,

WITH AND INTO "MILLENNIUM PHARMACEUTICALS, INC." UNDER THE NAME OF "MILLENNIUM PHARMACEUTICALS, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE TWELFTH DAY OF FEBRUARY, A.D. 2002, AT 6 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.



Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State

2322355 8100M

AUTHENTICATION: 1610075

CERTIFICATE OF OWNERSHIP AND MERGER

MERGING

COR THERAPEUTICS, INC.
(a Delaware corporation)

INTO

MILLENNIUM PHARMACEUTICALS, INC.
(a Delaware corporation)

Millennium Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "Corporation"), does hereby certify:

FIRST: That the Corporation was incorporated on the 13th day of January, 1993, pursuant to the General Corporation Law of the State of Delaware.

SECOND: That the Corporation owns all of the outstanding shares of each class of the stock of COR Therapeutics, Inc., a corporation incorporated on the 4th day of February, 1988 pursuant to the General Corporation Law of the State of Delaware.

THIRD: That the Board of Directors of the Corporation, by written action in lieu of a meeting dated the 4th day of February, 2002, duly adopted the following resolutions:

RESOLVED: That, pursuant to Section 253 of the Delaware General Corporation Law, the Corporation is hereby authorized to merge COR Therapeutics, Inc., a Delaware corporation which is a wholly owned subsidiary of the Corporation, into the Corporation;

RESOLVED: That the President and Secretary of the Corporation be, and each of them hereby is, authorized to execute a Certificate of Ownership and Merger with respect to the merger of COR Therapeutics, Inc. into the Corporation, cause the same to be filed with the Secretary of State of the State of Delaware and take all such other actions and to execute all such other instruments and agreements as the officer or officers so acting may deem appropriate to effect such merger;

RESOLVED: That the merger of COR Therapeutics, Inc. into the Corporation shall be effective upon the filing of a Certificate of Ownership and Merger with the Secretary of State of the State of Delaware.

IN WITNESS WHEREOF, the Corporation has caused this Certificate to be signed by its authorized officer this 12th day of February, 2002.

MILLENNIUM
PHARMACEUTICALS, INC.

By: /s/ Mark J. Levin
Title: President